. Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet. Am J Physiol Endocrinol Metab 305: E1415-E1425, 2013. First published October 15, 2013 doi:10.1152/ajpendo.00419.2013.-Because the renin-angiotensin-aldosterone system has been implicated in the development of insulin resistance and promotion of fibrosis in some tissues, such as the vasculature, we examined the effect of eplerenone, a selective mineralocorticoid receptor (MR) antagonist, on nonalcoholic steatohepatitis (NASH) and metabolic phenotypes in a mouse model reflecting metabolic syndrome in humans. We adopted liver-specific transgenic (Tg) mice overexpressing the active form of sterol response element binding protein-1c (SREBP-1c) fed a high-fat and fructose diet (HFFD) as the animal model in the present study. When wild-type (WT) C57BL/6 and liver-specific SREBP-1c Tg mice grew while being fed HFFD for 12 wk, body weight and epididymal fat weight increased in both groups with an elevation in blood pressure and dyslipidemia. Glucose intolerance and insulin resistance were also observed. Adipose tissue hypertrophy and macrophage infiltration with crown-like structure formation were also noted in mice fed HFFD. Interestingly, the changes noted in both genotypes fed HFFD were significantly ameliorated with eplerenone. HFFD-fed Tg mice exhibited the histological features of NASH in the liver, including macrovesicular steatosis and fibrosis, whereas HFFD-fed WT mice had hepatic steatosis without apparent fibrotic changes. Eplerenone effectively ameliorated these histological abnormalities. Moreover, the direct suppressive effects of eplerenone on lipopolysaccharide-induced TNF␣ production in the presence and absence of aldosterone were observed in primary-cultured Kupffer cells and bone marrow-derived macrophages. These results indicated that eplerenone prevented the development of NASH and metabolic abnormalities in mice by inhibiting inflammatory responses in both Kupffer cells and macrophages.
THE INCREASING PREVALENCE OF OBESITY and metabolic syndrome worldwide has been associated with the higher morbidity of nonalcoholic fatty liver disease (NAFLD) (10, 23, 29, 32) . NA-FLD includes a broad spectrum of manifestations of fatty liver ranging from simple steatosis to inflammatory nonalcoholic steatohepatitis (NASH) and cirrhosis (10, 26) . Because NASH has serious adverse effects on health, including hepatic failure, further understanding of its pathogenesis and the development of a novel effective therapeutic approach are needed. Recent studies have provided some notable animal models of NASH with obesity (12, 21) ; however, mouse models that more adequately reflect the clinical aspects of human NASH still need to be established.
The renin-angiotensin-aldosterone system (RAAS) is a coordinated hormonal cascade that maintains blood pressure and the salt-water balance (8) . Activation of the mineralocorticoid receptor (MR) has been implicated in the development of organ injury and promotion of fibrosis in the vasculature, cardiac muscle, and kidney (8, 9) . In addition, the local activation of RAAS was shown to participate in the development of local inflammation and insulin resistance (8) . These unfavorable effects of RAAS were considered to be induced mainly by angiotensin 2 (24, 38) ; however, recent studies indicated that local inflammation may promote the action of aldosterone or activation of MR during the development of insulin resistance in the adipose tissue of diabetic db/db and ob/ob mice (11, 13) . We confirmed that reactive oxygen species (ROS) mediated aldosterone-induced insulin resistance in 3T3-L1 adipocytes (36) . In addition, we reported the prominent therapeutic effect of an MR antagonist on the fatty liver and phenotypes of metabolic syndrome in C57BL/6 mice fed a high-fat and high-fructose diet (HFFD) (34) ; however, steatohepatitis with fibrosis did not develop in mice loaded with HFFD alone.
The transcriptional factor sterol response element-binding protein 1c (SREBP-1c) has been shown to play a central role in the regulation of lipid metabolism and lipogenesis (27) . A previous study reported that the expression of SREBP-1c was upregulated in the liver of patients with NASH (20) ; however, high-fat feeding failed to induce the upregulation of hepatic SREBP-1c in many strains of mice, including C57BL/6, due to a single nucleotide polymorphism in the promoter region (22, 34) . Therefore, we hypothesized that increased SREBP-1c may cause hepatic fibrosis in NAFLD under diet-induced obesity conditions. In the present study, we demonstrated that a transgenic mouse overexpressing the active form of SREBP-1c specifically in the liver (Tg) developed systemic insulin resistance and showed the phenotypes of NASH with the features of metabolic syndrome when mice were loaded with a 60% high-fat diet with 30% fructose water (HFFD) for 12 wk. Furthermore, we aimed to investigate the effect of eplerenone, a selective MR antagonist, on the development of NASH and metabolic abnormalities in this mouse model and explore the underlying mechanism.
MATERIALS AND METHODS
Animals and experimental design. The construction of liver-specific SREBP-1c transgenic mice expressing a constitutively active NH 2-terminal fragment of SREBP-1c was described previously (28) . This NH2-terminal fragment was shown to enter the nucleus without proteolytic release from the cell membrane being required and was prevented from being downregulated by sterols (28) . Mice were back-crossed with C57BL/6 mice more than 10 times. Tg mice and control wild-type (WT) mice were maintained under standard light (12:12-h light-dark cycle), temperature (24 Ϯ 1°C), and humidity (55 Ϯ 10%) conditions and were provided with food and water ad libitum. In the control group (WT RD ) or the group of Tg mice fed a regular diet (Tg RD ), mice were fed a regular diet composed of 4.8% fat (CE-12; Clea Japan, Tokyo, Japan) and water. In the group of WT (WT HFFD ) or Tg mice fed a high-fat diet with high-fructose water (Tg HFFD ), mice were fed 60% fat (D12492; Research Diets, New Brunswick, NJ) and 30% fructose water. In the eplerenone-treated WT (WT HFFD ϩ Ep ) or Tg mouse group (Tg HFFD ϩ Ep ), mice were fed 60% fat mixed with eplerenone (1.67 mg/g chow; provided by Pfizer, New York, NY) and 30% fructose water. After weaning, mice were fed each diet for 12 wk, and the phenotypes were then analyzed. All experimental procedures used in this study were approved by the Committee of Animal Experiments at the University of Toyama. Different numbers of mice were analyzed in some experiments because part of the group was used for histological analysis.
Measurements of serum parameters and glucose, insulin, and pyruvate tolerance tests. Mice were deprived of food overnight, and blood samples were collected from the orbital sinus under anesthesia. Serum glucose, insulin, HOMA-R index, and leptin levels were measured as described previously (34) . Other serum and urine biochemical analyses were determined by commercial kits (Wako Pure Chemical, Osaka, Japan, and Cayman Chemical, Ann Arbor, MI). Glucose, insulin, and pyruvate tolerance tests were conducted as described previously (34) .
Measurements of blood pressure and energy expenditure. Blood pressure and heart rate were measured by a blood pressure monitor for mice and rats (MK-2000ST; Muromachi Kikai, Tokyo, Japan), as described previously (34) . Oxygen consumption (V O2), carbon dioxide production (V CO2), locomotor activity, and the respiratory quotient ratio (RQ) were measured with a metabolism-measuring system for small animals (MK-5000RQ; Muromachi Kikai), as described previously (40) .
Measurements of hepatic triglyceride and collagen content. The hepatic triglyceride content was determined using a triglyceride colorimetric kit (Wako Pure Chemical) after extraction of the lipid fraction from frozen liver specimens by the method of Bligh and Dyer (3). The hepatic collagen content was determined using a collagen assay kit (Chondrex, Redmond, WA) according to the manufacturer's instructions.
Histological analysis. Mice were anesthetized and transcardially perfused with phosphate-buffered saline (PBS) followed by 4% paraformaldehyde (PFA). Liver and epididymal fat tissues were obtained, immersion-fixed in 4% PFA overnight, and embedded into paraffin. Six-micrometer-thick sections were then prepared and used for hematoxylin and eosin (HE), Azan, and Sirius-Red staining and also for immunohistochemistry. Frozen sections of formalin-fixed liver were stained with Oil Red O. The area of adipocytes in HE-stained epididymal fat tissue was traced and measured in 300 cells/mouse using a digital video analyzer (VH Analyzer VH-H1A5; Keyence, Osaka, Japan). The crown-like structure (CLS) was counted under a low-power field from each section using a microscope (BX61; Olympus, Tokyo, Japan) and is shown as the number of CLS per mm 2 . Paraffin-embedded sections for CD11c immunostaining were incubated with a hamster anti-mouse CD11c antibody (AbD-Serotec, Oxford, UK) for 3 h and then with a goat anti-hamster IgG antibody for 1 h (6).
Reverse transcription and real-time PCR. RNA extraction, reverse transcription, and real-time PCR using SYBR green were performed as described previously (7, 34, 35) . The primers for mouse MR and glucocorticoid receptor (GR) were prepared using a QuantiTect Primer assay system (Qiagen, Tokyo, Japan). The other primer pairs used are listed in Table 1 .
Preparation of primary Kupffer cells and bone marrow-derived macrophages. The livers of male Wistar rats were perfused with liver perfusion medium containing collagenase and pronase for the preparation of Kupffer cells. The liver suspension was filtrated, suspended in Gey's balanced salt solution, mixed with Nycodenz, and purified by centrifugal elutriation (2) . Isolated Kupffer cells were suspended in DMEM supplemented with 10% fetal calf serum at a concentration of 6 ϫ 10 6 cells/2 ml and plated onto six-well culture plates. Nonadherent cells were removed by aspiration after 1 h, and serum-deprived, steroid-free media were added. To prepare bone marrow-derived macrophages, the bone marrow was isolated from the femur and tibia of male C57BL/6J mice between 8 and 12 wk of age. Regarding differentiation, the bone marrow was maintained in RPMI 1640 medium supplemented with 100 ng/ml murine monocyte colonystimulating factor (R & D Systems, Minneapolis, MN) for 6 days. The purity of Kupffer cells and bone marrow-derived macrophages (Ͼ95%) was monitored by staining with an anti-F4/80 antibody.
Statistical analysis. Data are expressed as means Ϯ SE. P values were determined by a one-way ANOVA with Bonferroni's correction, and P Ͻ 0.05 was considered significant. 
MCP-1, monocyte chemotrractant protein-1; TGF␤, transforming growth factor-␤; ␣-SMA, ␣-smooth muscle actin; Col1␣1, collagen type 1-␣1; 11␤-HSD1, 11␤-hydroxysteroid dehydrogenase type 1.
RESULTS
Characteristics of WT and Tg mice after 12 wk of the food challenge. The characteristics of mice after 12 wk of the food challenge are shown in Table 2 . Body weight, liver weight, and epididymal fat weight were similar between WT and Tg mice under regular diet feeding. Although the total calorie intake was similar, body weight, epididymal fat weight, and liver weight were significantly heavier in mice fed HFFD and HFFD with eplerenone than in WT RD , respectively. Serum adiponectin levels were decreased by HFFD in Tg but not in WT mice, and the administration of eplerenone did not affect serum adiponectin levels in either genotype. Serum aspartate aminotransferase (AST) levels were elevated in both WT HFFD and Tg HFFD , whereas serum alanine aminotransferase levels were elevated in Tg HFFD . Elevations in these transaminases were again ameliorated by the treatment with eplerenone. Interestingly, the hepatic triglyceride content was significantly increased by HFFD, and the degree of lipid accumulation was more prominent in Tg HFFD than in WT HFFD . In addition, lipid accumulation was significantly ameliorated by the administration of eplerenone in both genotypes. Urinary excretion levels of aldosterone corrected by creatinine in WT HFFD and Tg HFFD were equivalent to those in WT RD and Tg RD ; however, they were elevated by the eplerenone treatment, which may have been due to negative feedback regulation in response to the MR blockade. In contrast, urine corticosterone levels were increased in WT HFFD and Tg HFFD and decreased by the treatment with eplerenone, which may have correlated with fat volumes.
Effect of eplerenone on impaired glucose tolerance, insulin resistance, and enhanced gluconeogenesis induced by HFFD.
Since eplerenone lowered serum glucose, insulin, and the HOMA-R index, we further characterized glucose metabolism in these mice (Fig. 2 ). Both WT HFFD and Tg HFFD showed a significant elevation in blood glucose levels during the glucose tolerance test (Fig. 2A) Red staining (Fig. 3, C and D) . In contrast, marked macrovesicular steatosis (Fig. 3, A and B) with the profound infiltration of proinflammatory cells consisting of polymorphonuclear leukocytes, eosinophils, and macrophages was observed under highpower field magnification in the liver of Tg HFFD (data not shown). In addition, perisinusoidal fibrosis in the centrilobular zone was observed in Tg HFFD (Fig. 3, C and D) , which indicated that Tg HFFD exhibited the apparent histological features of steatohepatitis. The liver of WT HFFD also showed macrovesicular hepatic steatosis, albeit to a lesser degree than that in Tg HFFD (data not shown), which was consistent with an increase in the hepatic triglyceride content (Fig. 1) (Fig. 4B) .
Eplerenone attenuated the upregulation of factors related to inflammation and fibrosis in the liver of Tg mice fed HFFD.
Since HFFD-induced steatohepatitis was observed only in Tg mice, we further investigated the expression profiles of hepatic factors that may be implicated in the pathophysiology of NASH. Concerning hepatic inflammation, expression levels of TNF␣ and monocyte chemoattractant protein-1 (MCP-1) were markedly elevated by HFFD, and the degree of elevation appeared to be more prominent in Tg HFFD than in WT HFFD . These elevations were significantly attenuated in both WT HFFD ϩ Ep and Tg HFFD ϩ Ep (Fig. 5A) . Expression of the monocyte cell marker F4/80 was higher in WT HFFD and Tg HFFD than in WT RD and Tg RD ; however, eplerenone did not affect its expression (Fig.  5A) . Consistent with the histological findings, the expression of transforming growth factor-␤ (TGF␤), a fibrosis-promotional cytokine, and ␣-smooth muscle actin (␣-SMA) and collagen type 1-␣1 (Col1␣1), two indicators of fibrosis, were significantly increased in Tg HFFD , and this increased expression was ameliorated in Tg HFFD ϩ Ep (Fig. 5B) . We further investigated the expression of aldosterone or corticosterone-related genes in the liver (Fig. 5C) . The hepatic . Serum and urinary profiles and hepatic triglyceride (TG) content in wild-type (WT) and liver-specific transgenic (Tg) mice. Serum measurements of glucose, insulin, HOMA-R, total cholesterol, triglyceride, leptin, adiponectin, aspartate aminotransferase (AST) and alanine aminotransferase (ALT), and urine aldosterone and corticosterone levels corrected by urine creatinine were analyzed (n ϭ 8 -14/group). To measure the triglyceride content in the liver, the lipid fraction was extracted from liver specimens, and the lipid content was determined by colorimetric measurements. Values are means Ϯ SE (n ϭ 6).
a P Ͻ 0. expression of Cyp11B2, an aldosterone synthase, and 11␤-hydroxysteroid dehydrogenase type 1 (11␤-HSD1), an enzyme that converts cortisone to active cortisol, was increased by HFFD but was significantly suppressed by eplerenone in both genotypes. Interestingly, the expression of both MR and GR in the liver was significantly elevated by HFFD, and these elevations were attenuated by the administration of eplerenone (Fig.  5C ). The expression of SREBP-1c was 1.3-fold higher in Tg than in WT, and HFFD further upregulated its expression in Tg mice but not in WT mice (Fig. 5D) . Eplerenone reduced adipocyte size and suppressed macrophage infiltration in the fat tissue of mice fed HFFD. Since MR antagonists have been shown to suppress adipose tissue inflammation in obese diabetic db/db and ob/ob mice (11, 13), we analyzed changes in the epididymal fat tissue of WT and Tg mice (Fig. 6) (Fig. 6B) . The adipocyte size was significantly decreased by the administration of eplerenone in both genotypes. Cell size distribution analyses demonstrated that the hypertrophic adipocytes observed in WT HFFD and Tg HFFD were markedly reduced by the treatment with eplerenone (data not shown). Consistent with adipocyte hypertrophy, the infiltration of M1 macrophages assessed by immunostaining with anti-CD11c was markedly increased in WT HFFD and Tg HFFD ; however, it appeared to decrease in eplerenone-treated mice (Fig. 6A) . Increased numbers of CLS, a cluster of macrophages surrounding a single adipocyte, formed in WT HFFD and Tg HFFD and were significantly reduced by the treatment with eplerenone (Fig. 6, A and C) . In accordance with these histological findings, the expression levels of mRNAs encoding for TNF␣, MCP1, and CD11c were also elevated in WT HFFD and Tg HFFD , and these levels were decreased or slightly decreased in eplerenone-treated mice (Fig. 7A) . Interestingly, the increased mRNA expression levels for 11␤-HSD1 and MR in WT HFFD and Tg HFFD were decreased or slightly decreased by the treatment with eplerenone (Fig. 7B) . Although the expression of GR mRNA in the adipose tissue was increased by HFFD, the eplerenone treatment did not affect the increased expression levels in both genotypes.
Eplerenone suppressed TNF␣ expression in Kupffer cells and macrophages. To further clarify the underlying molecular mechanism of action of eplerenone in preventing steatohepatitis in Tg HFFD , we finally examined the direct impact of the eplerenone treatment on the mRNA expression of TNF␣ induced by lipopolysaccharide (LPS) in primary Kupffer cells and bone marrow-derived macrophages (Fig. 8) . To avoid the effects of serum steroids and growth factors in the medium, isolated Kupffer cells and bone marrow-derived macrophages were maintained in culture medium without serum. Treatment with aldosterone (Fig. 8A ) or corticosterone alone (data not shown) did not have any effect on the expression of TNF␣. LPS significantly stimulated TNF␣ expression in Kupffer cells. Importantly, the treatment with aldosterone strongly augmented LPS-induced TNF␣ production, and pretreatment with eplerenone markedly suppressed this augmentation. In addition, eplerenone strongly suppressed TNF␣ expression induced by LPS alone (Fig. 8A) . Since chronic inflammation in the adipose tissue was also attenuated in eplerenone-treated mice, we further investigated the effect of eplerenone on TNF␣ expression in bone marrow-derived macrophages (Fig. 8B) . LPS-induced TNF␣ expression and its augmentation by aldosterone were also observed in macrophages. In addition, epler- enone effectively suppressed LPS-induced TNF␣ expression in the presence and absence of aldosterone.
DISCUSSION
Previous studies have attempted to establish an adequate mouse model of NASH with fibrosis (12, 21) . Although a mice model encompassing the full spectrum of human NASH disorder is currently not available, some NASH models mimic several important characteristics of human NASH (12, 21) . In the present study, we provided the first evidence to show that liver-specific SREBP-1c transgenic mice maintained on HFFD is a novel plausible model for human NASH because these mice had steatohepatitis with fibrosis in association with the phenotypes of metabolic syndrome, including obesity, glucose intolerance, insulin resistance, elevations in blood pressure, and dyslipidemia. Interestingly, HFFD feeding or the liverspecific transgenic overexpression of SREBP-1c alone did not cause steatohepatitis with fibrosis, at least in our experimental conditions.
Fructose is a lipogenic nutrient, and increased consumption of this monosaccharide has clearly been related to the current epidemiology of obesity and metabolic syndrome (25, 31) . In addition, continuous fructose consumption appears to be associated with the progression of fibrosis in patients with NAFLD (1). Previously, we characterized the metabolic phenotype of mice fed a 60% high-fat diet with 30% fructose-water for 8 wk (34) . Mice had the phenotypes of metabolic syndrome with simple hepatic steatosis; however, hepatic fibrosis was not observed. Importantly, in analyses of hepatic gene expression, SREBP-1c was not elevated in response to high-fat and high-fructose loading, whereas the marked upregulation of this gene was observed in the liver of patients with NASH (20) .
The absence of SREBP-1c upregulation in the liver by overnutrition has been observed in many strains of mice, including C57BL/6, which is in contrast to humans and other animal species. This difference has been attributed to a single nucleotide polymorphism in the promoter lesion of SREBP-1c in mice (22) . Since it is possible that the lack of diet-induced upregulation of SREBP-1c in the liver of mice may be related to the absence of hepatic fibrosis in HFFD-fed wild-type mice, we utilized transgenic mice overexpressing the active form of SREBP-1c, specifically in the liver, in the present study. Histological analyses demonstrated that Tg HFFD had apparent hypertrophy in the adipocyte size and CD11c-positive M1 macrophage infiltration arranged in the CLS formation in epididymal fat tissue. Moreover, the distinct histological features of steatohepatitis in the liver, including macrovesicular steatosis, the marked infiltration of inflammatory cells, and fibrotic changes, were observed. Since the overexpression of nSREBP-1c is hepatocyte specific under control of the phosphoenolpyruvate carboxykinase promoter in our Tg mice, the observed exacerbation of steatohepatitis may have been caused by excessive lipogenesis in the hepatocytes of Tg HFFD , which would lead to the additional development of inflammation and fibrosis in the liver. Although the expression of exogenous SREBP-1c was relatively modest (Fig. 5D) , Tg HFFD showed the apparent histological changes of steatohepatitis. Since ex- (16) . Importantly, the fibrotic cytokine TGF␤ and two indicators of HSC activation, ␣-SMA and Col1␣1, were markedly elevated in Tg HFFD . Therefore, severe lipid accumulation in the liver by SREBP-1c and the consequent production of TNF␣ by Kupffer cells may be important for the further exaggeration of inflammation and subsequent activation of the fibrogenic process. Thus, this mouse model appears to be valuable for further understanding the pathophysiology of NASH and evaluating the impact of the therapeutic agent.
Another major finding in the present study is that eplerenone, a selective MR antagonist, strongly prevented liver fibrosis associated with NASH as well as metabolic abnormalities in mice. Previous studies reported that MR antagonism significantly inhibited adipose tissue inflammation and improved systemic glucose metabolism in ob/ob and db/db mice (11, 13, 14) . Interestingly, the expression of MR in the adipose tissue and liver was higher in WT HFFD and Tg HFFD , and the upregulation of MR was ameliorated by the coadministration of eplerenone (Figs. 5 and 7) . We consider that the attenuation of hepatic ROS levels and inflammation may be the underlying mechanism of MR antagonism based on previous findings in adipocytes (11) . In the present study, we observed that eplerenone improved glucose and lipid metabolism and inhibited hypertrophy and inflammation in the adipose tissue of both WT HFFD and Tg
HFFD
. Moreover, we demonstrated that eplerenone prevented the development of hepatic fibrosis, as assessed by morphological changes, collagen content, and the expression levels of the fibrosis-related genes TGF␤, ␣-SMA, and Col1␣1 in the liver of Tg HFFD (Fig. 3, 4, and 5B). We further explored the mechanisms behind the beneficial effects of eplerenone and found that this reagent suppressed LPSinduced TNF␣ expression in both primary-cultured Kupffer cells and bone marrow-derived macrophages (Fig. 8) . These in vitro results suggest that not only macrophages in the adipose tissue but also Kupffer cells in the liver are the crucial targets of eplerenone to ameliorate local chronic inflammation and insulin resistance. The ablation of Kupffer cells and macrophages or inhibition of TNF␣ has been shown to ameliorate steatohepatitis and systemic glucose metabolism in obese animals (15, 17) .
Although the present findings, in which pretreatment with a physiological concentration of aldosterone enhanced LPS-induced TNF␣ expression and eplerenone abolished this enhancement (Fig. 8A) , suggest the crucial role of aldosterone in the proinflammatory response, no significant differences were observed in aldosterone excretion between the control and our NASH model mice (Fig. 1) . The local production of aldosterone in response to metabolic stress may have been involved in this process because CYP11␤2, an aldosterone synthase, was elevated in the liver of Tg HFFD (Fig. 5C) . Although the precise mechanism of CYP11␤2 upregulation remains unknown, local environmental factors may affect its expression, which is known to be upregulated in response to angiotensin 2 or serum glucose levels, at least in the kidney (39) .
Corticosterone can activate MR, especially in nonepithelial tissues, including macrophages, which do not express 11␤-HSD2 (18, 30) . Corticosterone at 10 Ϫ7 M has been shown to induce ROS production through MR in cultured adipocytes (14) . A low dose of corticosterone has been also shown to stimulate TNF␣ production in macrophages (18, 39) . We confirmed that the expression of 11␤-HSD2 in the epididymal fat and liver was not detected in the present real-time PCR experiments (data not shown). Since corticosterone was significantly elevated in Tg HFFD (Fig. 1) , we hypothesized that elevated corticosterone levels may have activated MR and enhanced the inflammatory process in Tg HFFD ; however, corticosterone alone did not enhance TNF␣ production at various concentrations in bone marrow-derived macrophages or primary Kupffer cells (data not shown). Moreover, LPS-induced TNF␣ expression was not affected by the pretreatment with corticosterone at 10 Ϫ12 or 10 Ϫ10 M, at least in our study, and was actually suppressed by a higher concentration of corticosterone (Ͼ10 Ϫ8 M), which has been attributed to the modulation of macrophage polarity toward an anti-inflammatory M2 phenotype (33) . Therefore, corticosterone-mediated activation of MR is unlikely to be involved in the enhancement of TNF␣ production in this model. Ϫ12 M was added 1 h after the Ep treatment. The cells were then stimulated with 100 ng/ml of LPS for 3 h and harvested. After the extraction of mRNA and reverse transcription, the relative expression levels of TNF␣ mRNA were determined by real-time PCR. Values are means Ϯ SE (n ϭ 6 -10). **P Ͻ 0.01, significantly different from the nontreated control; †P Ͻ 0.05 and † †P Ͻ 0.01, significant difference between the two groups, as indicated.
Interestingly, eplerenone inhibited LPS-induced TNF␣ expression in both Kupffer cells and macrophages under aldosterone/corticosterone-free conditions (Fig. 8) , which indicated that MR activity appears to be involved in the process of LPS-induced TNF␣ production through Toll-like receptor 4 signaling. The production of TNF␣ was recently shown to be enhanced in peritoneal macrophages derived from caveolin-1 (Cav1)-deficient mice (19, 37) . Since some portion of MR is known to be associated with Cav1 in vascular smooth muscle cells (4), MR blockade may affect signal transduction in caveolae by modulating Cav1 function in these cells. In addition, one can speculate that ROS production through MR activation in Kupffer cells is indispensable for the augmentation of robust inflammation, leading to the promotion of HSC activation and liver fibrosis. Further studies are needed to elucidate the mechanism for the anti-inflammatory effect of eplerenone.
Based on the present study, a schematic illustration of MR antagonism on the prevention of hepatic insulin resistance and fibrosis is shown in Fig. 9 . In the diet-induced obese condition, the liver is affected profoundly by excess nutrients and bacterial LPS from intestine and proinflammatory adipokines such as TNF␣ and free fatty acid (FFA) from enlarged fat tissue. Eplerenone effectively ameliorated adipose tissue inflammation and steatohepatitis. In the liver, FFA and LPS stimulate Kupffer cells and TNF␣ production, which is known to activate HSC, leading to the promotion of fibrotic process. TNF␣ concomitantly affects hepatocytes and induces insulin resistance. Eplerenone effectively attenuates Kupffer cell activation and TNF␣ production; therefore, hepatic fibrosis, insulin resistance, and lipogenesis are subsequently ameliorated. Although we proposed mechanisms for the amelioration of both insulin resistance and steatohepatitis by eplerenone, we cannot rule out the possibility that another mechanism, including the direct inhibition of MR in hepatocytes, may exist. Further studies are needed to more precisely understand MR inhibition on the amelioration of metabolism.
In summary, we designed a new mouse model of NASH associated with the pathophysiology of metabolic syndrome in humans, using liver-specific SREBP-1c transgenic mice. This animal model appears to be relevant to the early stage of NASH progression in humans and is useful for further understanding the pathophysiology of NASH. Eplerenone effectively ameliorated metabolic abnormalities, inflammation in adipose tissue, steatohepatitis, and hepatic fibrosis, possibly via the suppression of TNF␣ production in Kupffer cells in the liver as well as macrophages in the adipose tissue. These results provide new insights into therapeutic strategies on the basis of MR blockade to prevent the development of NASH and its causal dysregulation of glucose and lipid metabolism in the metabolic syndrome. . Schematic illustration of the effect of Ep on the amelioration of hepatic fibrosis and insulin resistance in mice. In the diet-induced obese condition, the liver is affected profoundly by excess nutrients and bacterial LPS from the intestine. In addition, proinflammatory adipokines such as TNF␣ and free fatty acid (FFA) also flow into the liver. These factors contribute to the development of fatty liver disease, in which MR activation appears to be involved in the development of chronic inflammation in the liver and adipose tissue. The administration of Ep effectively ameliorates these inflammatory processes in the progression of nonalcoholic steatohepatitis. Ep prevents FFA and LPS-induced stimulation of Kupffer cells and TNF␣ production, which is known to activate hepatic stellate cells (HSC), thereby promoting fibrotic process. Ep also effectively ameliorates hepatic insulin resistance and lipogenesis induced by TNF␣ in hepatocytes.
